Q4 2023
Released Mar 1, 2024, before the open
10-K filed Mar 1, 2024, 61 days after period end · 0001628280-24-008116
Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00 derivedno prior Q4 2022 on fileno prior Q3 2023 on file
Net Income-$65.64M-$65.64M derivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$68,043,000N/M
Operating Cash Flowderived-$43,864,000N/M
Free Cash Flowderived-$45,704,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|
| Revenue | $0.00 | — | — |
| Net Income | -$65.64M | -$39.28M | -$62.91M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR